Assessing OATP1B1- and OATP1B3-mediated drug-drug interaction potential of vemurafenib using R-value and physiologically based pharmacokinetic models.

Organic anion transporting polypeptides (OATP) 1B1 and OATP1B3 are important determinants of transporter-mediated drug-drug interactions (DDIs). Current studies assessed the OATP1B1 and OATP1B3-mediated DDI potential of vemurafenib, a kinase inhibitor drug with high protein binding and low aqueous solubility, using R-value and physiologically based pharmacokinetic (PBPK) models. The total half-maximal inhibitory concentration (IC50,total) values of vemurafenib against OATP1B1 and OATP1B3 were determined in 100% human plasma in transporter-overexpressing human embryonic kidney 293 stable cell lines. The unbound fraction of vemurafenib in human plasma before (fu,plasma) and after addition into the uptake assay plate (fu,plasma,inc) were determined by rapid equilibrium dialysis. There was no statistically significant difference between fu,plasma and fu,plasma,inc. Vemurafenib IC50,total values against OATP1B1 and OATP1B3 are 175 ± 82 and 231 ± 26 μM, respectively. The R-values [R = 1 + fu,plasma × Iin,max/(fu,plasma,inc × IC50,total)] were then simplified as R=1+Iin,max/IC50,total, and were 1.76 and 1.57 for OATP1B1 and OATP1B3, respectively. The simulated pravastatin AUC ratio was 1.28 when a single dose of pravastatin (40 mg) was co-administered with vemurafenib (960 mg, twice daily) at steady-state, compared to pravastatin alone. Both R-value and PBPK models predict that vemurafenib has the potential to cause OATP1B1- and OATP1B3-mediated DDIs.

• Publication year

  2020

• Venue

  Journal of Pharmacy and Science

• Publication date

  2020-06-23

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/j.xphs.2020.06.016PMID 32590030PMCID PMC7750294
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Preincubation With Everolimus and Sirolimus Reduces Organic Anion-Transporting Polypeptide (OATP)1B1- and 1B3-Mediated Transport Independently of mTOR Kinase Inhibition: Implication in Assessing OATP1B1- and OATP1B3-Mediated Drug-Drug Interactions.

  2019cited by this paper
• Effect of Vemurafenib on the Pharmacokinetics of a Single Dose of Digoxin in Patients With BRAFV600 Mutation–Positive Metastatic Malignancy

  2018cited by this paper
• Pretreatment With Rifampicin and Tyrosine Kinase Inhibitor Dasatinib Potentiates the Inhibitory Effects Toward OATP1B1- and OATP1B3-Mediated Transport.

  2017cited by this paper
• Treatment with proteasome inhibitor bortezomib decreases organic anion transporting polypeptide (OATP) 1B3-mediated transport in a substrate-dependent manner

  2017cited by this paper
• Clinical Pharmacokinetics of Vemurafenib

  2017cited by this paper
• Validation of a total IC50 method which enables in vitro assessment of transporter inhibition under semi-physiological conditions

  2017cited by this paper
• Industry Perspective on Contemporary Protein-Binding Methodologies: Considerations for Regulatory Drug-Drug Interaction and Related Guidelines on Highly Bound Drugs.

  2017cited by this paper
• Comparing Various In Vitro Prediction Criteria to Assess the Potential of a New Molecular Entity to Inhibit Organic Anion Transporting Polypeptide 1B1

  2016cited by this paper
• The Application of Physiologically Based Pharmacokinetic Modeling to Predict the Role of Drug Transporters: Scientific and Regulatory Perspectives

  2016cited by this paper
• Downregulation of Organic Anion Transporting Polypeptide (OATP) 1B1 Transport Function by Lysosomotropic Drug Chloroquine: Implication in OATP-Mediated Drug-Drug Interactions.

  2016cited by this paper
• Plasma Protein Binding of Challenging Compounds.

  2015cited by this paper
• Investigation of the Impact of Substrate Selection on In Vitro Organic Anion Transporting Polypeptide 1B1 Inhibition Profiles for the Prediction of Drug-Drug Interactions

  2015cited by this paper
• The effects of a high‐fat meal on single‐dose vemurafenib pharmacokinetics

  2014cited by this paper
• Inhibition of OATP1B1 by tyrosine kinase inhibitors: in vitro–in vivo correlations

  2014cited by this paper
• A mass balance approach for calculation of recovery and binding enables the use of ultrafiltration as a rapid method for measurement of plasma protein binding for even highly lipophilic compounds.

  2013cited by this paper
• A phase I, randomized, open-label study of the multiple-dose pharmacokinetics of vemurafenib in patients with BRAFV600E mutation-positive metastatic melanoma

  2013cited by this paper
• Contribution of OATP1B1 and OATP1B3 to the Disposition of Sorafenib and Sorafenib-Glucuronide

  2013cited by this paper
• Small molecule kinase inhibitors approved by the FDA from 2000 to 2011: a systematic review of preclinical ADME data

  2013cited by this paper
• Drug-Drug Interactions between Rosuvastatin and Oral Antidiabetic Drugs Occurring at the Level of OATP1B1

  2013cited by this paper
• Substrate-Dependent Inhibition of Organic Anion Transporting Polypeptide 1B1: Comparative Analysis with Prototypical Probe Substrates Estradiol-17β-Glucuronide, Estrone-3-Sulfate, and Sulfobromophthalein

  2013cited by this paper
• Cyclosporine Inhibition of Hepatic and Intestinal CYP3A4, Uptake and Efflux Transporters: Application of PBPK Modeling in the Assessment of Drug-Drug Interaction Potential

  2013cited by this paper
• Imaging of TKI–Target Interactions for Personalized Cancer Therapy

  2013cited by this paper
• Application of permeability-limited physiologically-based pharmacokinetic models: part II - prediction of P-glycoprotein mediated drug-drug interactions with digoxin.

  2013cited by this paper
• Impact of P-Glycoprotein (ABCB1) and Breast Cancer Resistance Protein (ABCG2) on the Brain Distribution of a Novel BRAF Inhibitor: Vemurafenib (PLX4032)

  2012cited by this paper
• Long-lasting inhibitory effects of cyclosporin A, but not tacrolimus, on OATP1B1- and OATP1B3-mediated uptake.

  2012cited by this paper
• Validation of 96-well equilibrium dialysis with non-radiolabeled drug for definitive measurement of protein binding and application to clinical development of highly-bound drugs.

  2011cited by this paper
• Differential effect of grapefruit juice on intestinal absorption of statins due to inhibition of organic anion transporting polypeptide and/or P-glycoprotein.

  2011cited by this paper
• Predictive Utility of In Vitro Rifampin Induction Data Generated in Fresh and Cryopreserved Human Hepatocytes, Fa2N-4, and HepaRG Cells

  2011cited by this paper
• Evaluation of in situ albumin binding surfaces: a study of protein adsorption and platelet adhesion

  2011cited by this paper
• Tyrosine kinase blockers: new hope for successful cancer therapy.

  2009cited by this paper
• Physiologically Based Pharmacokinetic Modeling to Predict Transporter-Mediated Clearance and Distribution of Pravastatin in Humans

  2009cited by this paper
• Prediction of Human Pharmacokinetics From Preclinical Information: Comparative Accuracy of Quantitative Prediction Approaches

  2009cited by this paper
• Drug–Drug Interactions Mediated Through P‐Glycoprotein: Clinical Relevance and In Vitro–In Vivo Correlation Using Digoxin as a Probe Drug

  2009cited by this paper
• Effects of a concomitant single oral dose of rifampicin on the pharmacokinetics of pravastatin in a two-phase, randomized, single-blind, placebo-controlled, crossover study in healthy Chinese male subjects.

  2009cited by this paper
• Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions.

  2006cited by this paper
• Drug interactions with lipid‐lowering drugs: Mechanisms and clinical relevance

  2006cited by this paper
• Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitors.

  2004cited by this paper
• PACKAGE INSERT

  2004cited by this paper
• Contribution of OATP2 (OATP1B1) and OATP8 (OATP1B3) to the Hepatic Uptake of Pitavastatin in Humans

  2004cited by this paper
• Effect of rifampicin on pravastatin pharmacokinetics in healthy subjects.

  2003cited by this paper
• A novel human organic anion transporting polypeptide localized to the basolateral hepatocyte membrane.

  2000cited by this paper
• Localization and Genomic Organization of a New Hepatocellular Organic Anion Transporting Polypeptide*

  2000cited by this paper
• Comparison of cytochrome P-450-dependent metabolism and drug interactions of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors lovastatin and pravastatin in the liver.

  1999cited by this paper
• Modulation of cholecystokinin activity by albumin.

  1995cited by this paper
• High-performance frontal analysis for the study of protein binding of troglitazone (CS-045) in albumin solution and in human plasma.

  1995cited by this paper
• Equilibrium dialysis, ultrafiltration, and ultracentrifugation compared for determining the plasma-protein-binding characteristics of valproic acid.

  1985cited by this paper
• Binding of rifampicin by human plasma proteins

  1974cited by this paper
• Competitive binding of free and conjugated oestrogens to plasma proteins.

  1969cited by this paper
• Adsorption of plasma proteins in solution to uncharged, hydrophobic polymer surfaces.

  1969cited by this paper
• THE ESTIMATION OF HEPATIC BLOOD FLOW IN MAN.

  1945cited by this paper

• Alterations of valsartan pharmacokinetics in a rodent model of metabolic dysfunction-associated steatohepatitis.

  2025cites this paper
• Integrated pharmacokinetics and multidimensional drug-drug interactions assessment of bufadienolides based on UPLC-QqQ-MS/MS.

  2025cites this paper
• Application of physiologically based pharmacokinetics modeling in the research of small-molecule targeted anti-cancer drugs

  2023cites this paper
• Differential Preincubation Effects of Nicardipine on OATP1B1- and OATP1B3-Mediated Transport in the Presence and Absence of Protein: Implications in Assessing OATP1B1- and OATP1B3-Mediated Drug–Drug Interactions

  2023cites this paper
• Predicting transporter mediated drug–drug interactions via static and dynamic physiologically based pharmacokinetic modeling: A comprehensive insight on where we are now and the way forward

  2022cites this paper
• Novel inhibitors of breast cancer resistance protein (BCRP, ABCG2) among marketed drugs.

  2022cites this paper
• Cancer-Type Organic Anion Transporting Polypeptide 1B3 Is Localized in Lysosomes and Mediates Resistance against Kinase Inhibitors

  2022cites this paper
• Influence of Tyrosine Kinase Inhibition on Organic Anion Transporting Polypeptide 1B3-Mediated Uptake

  2022influential citation
• Angiotensin II receptor blockers (ARBs) and manufacturing contamination: A retrospective National Register Study into suspected associated adverse drug reactions

  2022influential citation
• Impact of Morus alba L. on the expression of drug-metabolizing enzymes and transporters in Caco-2 cells

  2022cites this paper
• Impact of Pineapple on Mitochondrial Permeability Transition and Drug Metabolizing Genes in Caco-2 Cells.

  2021cites this paper
• Impact of Pineapple Juice on Expression of CYP3A4, NAT2, SULT1A1 and OATP1B1 mRNA in HepG2 Cells.

  2021cites this paper
• Drug Transport—Uptake

  2021cites this paper